PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26025F0024Berotralstat HCL 150mg CAP ORAL orladeyo — Biocryst Pharmaceuticals, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Sep 30, 2025 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

260-Network Contract Office 20 (36C260)

Awarding office

Biocryst Pharmaceuticals, Inc

Recipient

Sep 30, 2025

PoP end

$380K

Obligated

$380K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Biocryst Pharmaceuticals, Inc — $90

Contract facts

Federal

Contract number36C26025F0024

Also listed as36C260-25-F-0024

Also listed as36F79721D0166-36C26025F0024

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentBiocryst Pharmaceuticals, Inc

CAGE4GBX7

UEIMGXADJ6SCLJ5

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79721D0166

Place of performanceEARTH CITY MO

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startOct 1, 2024

PoP end (current)Sep 30, 2025

Obligated$380K

Current value$380K

Potential value$380K

BEROTRALSTAT HCL 150MG CAP,ORAL (ORLADEYO). is a federal award for 260-Network Contract Office 20 (36C260) held by Biocryst Pharmaceuticals, Inc. Estimated value $380K ($380K obligated). Current period of performance ends Sep 30, 2025. Last award drew 1 bidder. Place of performance: EARTH CITY MO.

BEROTRALSTAT HCL 150MG CAP,ORAL (ORLADEYO).

Recompete timing

Public

● Past PoP end (325 days ago)

Current PoP ended Sep 30, 2025 (325 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26025F0024?

36C26025F0024 (Berotralstat HCL 150mg CAP ORAL orladeyo) is a 260-Network Contract Office 20 (36C260) award with a potential value of $380K, currently held by Biocryst Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-25-F-0024?

36C260-25-F-0024 is the dashed form of PIID 36C26025F0024 (Berotralstat HCL 150mg CAP ORAL orladeyo), held by Biocryst Pharmaceuticals, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26025F0024?

260-Network Contract Office 20 (36C260) awarded 36C26025F0024 to Biocryst Pharmaceuticals, Inc (potential $380K).

Who is the incumbent on 36C26025F0024?

Biocryst Pharmaceuticals, Inc is the incumbent. The current period of performance ends Sep 30, 2025.

When does Biocryst Pharmaceuticals, Inc’s 36C26025F0024 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2025. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2025 · refreshed monthly